Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AMA Discourages Physician Sale Of "Health-Related Products"

This article was originally published in The Tan Sheet

Executive Summary

American Medical Association voluntary guidelines adopted at the group's annual meeting in Chicago June 20-24 discourage physician in-office sale of "health-related products." The practice "presents a financial conflict of interest, risks placing undue pressure on the patient, and threatens to erode patient trust and the primary obligation of physicians to serve the interests of their patients before their own," an AMA report states.

You may also be interested in...



Point-Of-Care Supplement Delivery With Drugs Proposed

Providing dietary supplements at the point of care would improve the public's health and more adequately ensure the products are being used correctly, according to Global Health Sciences Senior VP Alan Xenakis, MD/PhD.

Point-Of-Care Supplement Delivery With Drugs Proposed

Providing dietary supplements at the point of care would improve the public's health and more adequately ensure the products are being used correctly, according to Global Health Sciences Senior VP Alan Xenakis, MD/PhD.

Point-Of-Care Supplement Delivery With Drugs Proposed

Providing dietary supplements at the point of care would improve the public's health and more adequately ensure the products are being used correctly, according to Global Health Sciences Senior VP Alan Xenakis, MD/PhD.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090004

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel